This New Medicare Pilot Program Offers GLP-1s For $50 A Month. Here’s What You Need To Know
Medicare has launched a new pilot program called Bridge that allows eligible beneficiaries to access GLP-1 obesity drugs from Novo Nordisk and Eli Lilly for $50 per month, a dramatic reduction from hundreds of dollars. However, the program faces implementation challenges and is only guaranteed through the end of 2027, creating uncertainty for patients starting long-term therapies.
Summary
Starting this week, millions of eligible Medicare patients gain access to GLP-1 obesity drugs through a new federal pilot program called Bridge, marking a significant shift in Medicare policy. Traditionally, Medicare has barred coverage of medications prescribed solely for obesity, but this program creates a temporary pathway for coverage. Eligible beneficiaries must meet certain requirements, including a BMI over 35 and the presence of certain obesity-related conditions, and can access these medications for a $50 monthly copay instead of the typical hundreds of dollars per month. This move could potentially reach as many as 20 million new patients according to Novo Nordisk and Eli Lilly's estimates, with officials expecting several million beneficiaries to enroll immediately. The program addresses a significant access gap for older Americans who have been unable to afford these popular weight loss drugs. However, the rollout faces practical challenges. Doctors must submit prior authorization requests to confirm patient eligibility before coverage is approved, and physicians are concerned that an influx of new patients could strain already busy clinics and pharmacies. More critically, the coverage is not permanent—unless the Trump administration extends or replaces the program, Bridge coverage is scheduled to expire by the end of 2027, and any permanent changes would require congressional approval. This creates a significant risk for patients who will begin long-term obesity therapies without knowing whether coverage will continue beyond 2027.
Key Insights
- GLP-1 obesity drugs have cost hundreds of dollars per month, making them out of reach for most older Americans on Medicare until this week's program launch
- The Bridge program represents a major shift because Medicare has traditionally barred coverage of medications prescribed solely for obesity
- Novo Nordisk and Eli Lilly estimate the program could reach as many as 20 million eligible patients, with several million expected to enroll immediately
- Physicians warn that a wave of new patients could put additional pressure on already busy clinics and pharmacies over the next couple of months
- The coverage through Bridge is scheduled to expire by the end of 2027 unless the Trump administration extends it, and permanent changes would require congressional approval
Topics
Transcript
[0:00] Popular weight loss drugs have remained out of reach for most older Americans in Medicare for years. That's because GLP-1s can cost hundreds of dollars per month, but that changes this week. Starting Wednesday, millions of eligible Medicare patients can access GLP-1 obesity drugs >> [music] >> from Novo Nordisk and Eli Lilly for a copay of just $50 per month. It's a major shift for a federal program that has traditionally barred coverage of medications prescribed solely for obesity. So, what happened? Well, there's a new Medicare pilot program called Bridge that's creating a temporary pathway for coverage. Patients [0:31] who meet [music] certain requirements, including those with a BMI of over 35 and people with certain obesity-related…
Full transcript available for MurmurCast members
Sign Up to AccessMore from CNBC
The Fed’s Plan To Restore Price Stability Relies On AI
Federal Reserve Chair Kevin Worsh testified to Congress on monetary policy, emphasizing that inflation has remained above the Fed's 2% target for 63 consecutive months and that real wages have stagnated despite nominal increases. Worsh has established an AI task force to explore productivity gains as justification for potential future interest rate cuts, though his colleagues remain skeptical of the promised AI productivity boom.
How Chinese Automakers Like Geely And BYD Are Taking Over The UK
Chinese automakers like Geely and BYD have captured over 30% of the UK EV market by offering superior technology and pricing 5-10,000 pounds below comparable European models, driven by Chinese government subsidies. This surge is forcing legacy automakers and Tesla to compete with new strategies, with Chinese exports to Europe exploding from 100,000 to 1.7 million vehicles in five years.
Why Prediction Markets Are So Hard To Regulate
Prediction markets are growing rapidly but face regulatory uncertainty as the CFTC and SEC debate jurisdiction. The key challenge is determining which agency regulates contracts tied to publicly traded companies, with the term "directly affects" remaining ambiguous since the 2010 Dodd-Frank law.
Elon Musk’s Memphis Takeover — The Marvels And Messiness Of SpaceX’s AI Buildout
XAI/SpaceX's rapid construction of massive AI data centers in Memphis and South Haven has created significant environmental and quality-of-life issues for residents, including noise pollution, air quality concerns, and water consumption, while generating billions in revenue despite operating many turbines without proper permits.
Energy Prices Ease In June, Dropping U.S. Inflation To 3.5% Annually
U.S. inflation dropped to 3.5% in June, the first monthly decrease of 2024, primarily driven by a 15.7% energy index decline tied to falling oil prices and increased tanker traffic through the Strait of Hormuz. Core inflation remains elevated at 2.6%, while emerging pressures from AI-driven demand for memory chips and tariffs are pushing up prices for computers, clothing, and electricity.